glycyrrhetyl 3-monoglucuronide: RN given for (3beta,20beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
glycyrrhetic acid 3-O-glucuronide : A triterpenoid saponin that is the 3-O-beta-glucuronide of glycyrrhetic acid. It is a metabolite of glycyrrhizin contained in licorice and potentially a causative agent in the pathogenesis of pseudoaldosteronism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 161800 |
| CHEBI ID | 189708 |
| MeSH ID | M0148759 |
| Synonym |
|---|
| 3-monoglucuronyl glycyrrhetinic acid |
| 3-monoglucuronyl-glycyrrhetinic acid |
| starrhizin |
| 3-mga |
| glycyrrhetinic acid 3-o-mono-beta-d-glucuronide |
| (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl beta-d-glucopyranosiduronic acid |
| glycyrrhetyl 3-monoglucuronide |
| 18beta-glycyrrhetinic acid-3-o-beta-d-glucuronide |
| glycyrrhetic acid 3-o-beta-d-glucuronide |
| CHEBI:189708 |
| 3beta-d-(monoglucuronyl)-18beta-glycyrrhetinic acid |
| 3-o-glucuronopyranosylglycyrrhetinic acid |
| 18beta-glycyrrhetyl-3-o-glucuronide |
| glycyrrhetinic acid 3-o-glucuronide |
| 3-o-beta-d-glucuronopyranosyl-18beta-glycyrrhetinic acid |
| 30-hydroxy-11,30-dioxoolean-12-en-3beta-yl beta-d-glucopyranosiduronic acid |
| glycyrrhetic acid 3-o-glucuronide |
| glycyrrhetinic acid acid 3-o-beta-d-glucuronide |
| glycyrrhetic acid 3-o-mono-beta-d-glucuronide |
| glycyrrhetinic acid 3-o-monoglucuronide |
| (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid |
| 1-(18beta-glycyrrhet-3-yl)glucopyranuronic acid |
| 3-(monoglucuron-1'-yl)-18-glycyrrhetic acid |
| beta-d-glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl |
| glycyrrhetic acid 3-o-|a-d-glucuronide |
| (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid |
| AKOS027382832 |
| glycyrrheticacid3-o-glucuronide |
| HY-N6851 |
| CS-0100277 |
| MS-30945 |
| 29-hydroxy-11,29-dioxoolean-12-en-3-yl hexopyranosiduronic acid |
| DTXSID70955639 |
| glycyrrhetic acid 3-o--d-glucuronide |
| FJL , |
| (2~{s},3~{s},4~{s},5~{r},6~{r})-6-[[(3~{s},4~{a}~{r},6~{a}~{r},6~{b}~{s},8~{a}~{s},11~{s},12~{a}~{r},14~{a}~{r},14~{b}~{s})-11-carboxy-4,4,6~{a},6~{b},8~{a},11,14~{b}-heptamethyl-14-oxidanylidene-2,3,4~{a},5,6,7,8,9,10,12,12~{a},14~{a}-dodecahydro-1~{h}-p |
| Excerpt | Relevance | Reference |
|---|---|---|
| " While treatment with a low dosage of furosemide had no effect on PPL, the multiple administration of GL and furosemide markedly decreased PPL compared to the effect of administering GL alone." | ( A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism. Kase, Y; Kido, A; Kubota, K; Morita, T; Ohtake, N; Takeda, S; Tsuchiya, N, 2007) | 0.34 |
| Role | Description |
|---|---|
| anti-allergic agent | A drug used to treat allergic reactions. |
| sweetening agent | Substance that sweeten food, beverages, medications, etc. |
| EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor | An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of 11beta-hydroxysteroid dehydrogenase (EC 1.1.1.146). |
| human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| beta-D-glucosiduronic acid | A glucosiduronic acid resulting from the formal condensation of any substance with beta-D-glucuronic acid to form a glycosidic bond. |
| triterpenoid saponin | A terpene glycoside in which the terpene moiety is a triterpenoid. |
| pentacyclic triterpenoid | |
| oxo dicarboxylic acid | Any dicarboxylic acid carrying one or more oxo groups. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (95.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||